Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.
about
The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumorsExploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer.Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.BEAMing up personalized medicine: mutation detection in bloodPIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trialsMeasurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer.New targetable oncogenes in non-small-cell lung cancer.Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer.Molecular analysis of a male breast cancer patient with prolonged stable disease under mTOR/PI3K inhibitors BEZ235/everolimus.The molecular diversity of Luminal A breast tumors.Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients.Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway.Advances in the approach to novel drug clinical development for breast cancer.PI3K/AKT signaling pathway and cancer: an updated review.PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment.Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer.
P2860
Q33937368-6E75819C-C548-42E1-995B-63B6F6E69313Q33999493-C97DC19B-167D-4517-8C8B-4FE0CF708F94Q35051964-36960C19-0F40-4612-872E-1A45C2C3EA80Q35453467-497419FA-C3E3-404C-83ED-BCF275974E2FQ35680026-E32A3979-B7DB-48F2-9082-371DF3095513Q36040951-3FD54BD5-C62E-4BC9-BFE3-CA8840E1A3F0Q36510935-83572CB4-BCF5-4FCF-A2D1-22249F32DA92Q36557786-8C605766-E648-4B36-94FF-B48D0A946819Q36660677-D58496FB-11C9-483A-8762-F3A60C8E338AQ36703783-7835726F-C379-4717-AD40-6DCD5E467390Q36849266-EF7F9EB5-1D1C-4BE1-93FF-4678F66FBE41Q37298868-2B0F55C8-142C-4A3E-A623-EDDD83D0B4C7Q37350792-EDCBC1EA-621B-483C-8B4B-897E42ED2EE8Q37421358-2EC72DD4-E42D-4C21-ADCE-396F1B1F37BDQ37444430-55A85D48-EF96-40FF-B26A-3C1FCC6D29F5Q38100719-06591AF4-22C9-4745-8A12-86AB38E5A2EFQ38206546-4AD105F1-B0D6-410F-A147-33B38740E3BBQ38217651-EA88DA49-D03C-4FE2-9F92-E0BA0575EA05Q39108771-102A0F5F-73B5-454A-B11E-E13BC981840AQ39226360-2D53AD5D-195C-4968-9F05-2B79047600F1Q44581657-C4FC459C-776F-4FFF-AF4C-31FB5882479FQ47564750-D09B2DE0-EEC2-46BB-A584-3B6011B478DA
P2860
Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Tumor genetic testing for pati ...... : the case of PI3K inhibitors.
@en
Tumor genetic testing for pati ...... : the case of PI3K inhibitors.
@nl
type
label
Tumor genetic testing for pati ...... : the case of PI3K inhibitors.
@en
Tumor genetic testing for pati ...... : the case of PI3K inhibitors.
@nl
prefLabel
Tumor genetic testing for pati ...... : the case of PI3K inhibitors.
@en
Tumor genetic testing for pati ...... : the case of PI3K inhibitors.
@nl
P356
P1476
Tumor genetic testing for pati ...... : the case of PI3K inhibitors.
@en
P2093
Dejan Juric
José Baselga
P304
P356
10.1200/JCO.2011.39.6390
P407
P577
2012-01-23T00:00:00Z